| 名称 | SBI-0640756 |
| 描述 | SBI-0640756 (SBI-756) (SBI-756) is a first-in-class inhibitor that targets eIF4G1 and disrupts the eIF4F complex. |
| 细胞实验 | Cells were rinsed with PBS and lysed as previously described. Protein concentration was determined using Coomassie Plus Protein Assay Reagent. Equal amounts of cell lysate proteins (50 μg) were separated on SDS-PAGE and transferred to polyvinylidene difluoride membranes. Membranes were blocked (5% BSA/TBST, 1 h) and incubated with primary antibodies (1 h at room temperate or overnight at 4°C), with shaking. Following three TBST washes, membranes were incubated for 1 h at room temperature secondary antibodies (1:10,000). Detection and quantifications were made using Odyssey Infrared Imaging System, or by exposing them to X-ray film. Antibodies against p-AKT, p-PRAS40, p-IKK, p-IκB, p-TSC, p-mTOR, p-p70S6K, p-RPS6, p-4E-BP1, pSGK3, AKT, PRAS40, IKK, IκB, mTOR, p70S6K, RPS6, 4E-BP1, GSK3, eIF4G1, and eIF4E were purchased from Cell Signaling Technology. Antibodies against β-actin and α-tubulin were obtained from Santa Cruz Biotechnology. Secondary antibodies were goat anti-rabbit Alexa-680 F(ab')2 and goat anti-mouse IRDye 800 F(ab')2. All antibodies were used according to the suppliers' recommendations. |
| 体外活性 | SBI-0640756 effectively dissociated eIF4G1 from the eIF4E in a dose-dependent manner, which was accompanied by a concomitant increase in 4E-BP1:eIF4E binding, reflective of impaired eIF4F complex formation. SBI-0640756 also inhibits the AKT/mTORC1 signaling and mTORC1 inhibition disrupts the eIF4F complex via activation of 4E-BPs. Whereas torin1 induced dissociation of eIF4G1 from eIF4E in WT but not in 4E-BP DKO MEFs, SBI-0640756 reduced eIF4G1:eIF4E association in both WT and 4E-BP DKO MEFs. Likewise, SBI-0640756 but not torin1 attenuated the proliferation of E1A/RAS-transformed 4E-BP DKO MEFs. |
| 体内活性 | Administration of SBI-0640756 only, starting 11 weeks after genetic inactivation of Ink4a and induction of NRasQ61E (about 10–14 days prior to tumor appearance), delayed tumor onset (from 20–26 weeks) and reduced tumor incidence, by 50%, compared with the control non-treated group. The growth of established tumors was largely inhibited by treatment with either BRAFi alone or a combination of BRAFi plus SBI-0640756. |
| 存储条件 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| 溶解度 | H2O : Insoluble
DMSO : 50 mg/mL (123.51 mM)
|
| 关键字 | Autophagy | SBI-0640756 | Inhibitor | SBI 756 | SBI756 | Eukaryotic Initiation Factor (eIF) | inhibit | SBI0640756 |
| 相关产品 | Stavudine | Xylitol | Myricetin | Sodium 4-phenylbutyrate | Hydroxychloroquine | Guanidine hydrochloride | Taurine | Curcumin | Oxyresveratrol | Paeonol | Naringin | Gefitinib |
| 相关库 | 细胞凋亡化合物库 | 细胞重编程化合物库 | 经典已知活性库 | 内质网应激化合物库 | 激酶抑制剂库 | 自噬库 | 抑制剂库 | NO PAINS 化合物库 | 抗衰老化合物库 | 已知活性化合物库 |
United States
